Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Wirth

Showing results (351-360 of 392) with videos related to

Pageof 40
Sort By:
Annals of Neurology|August 4, 2020
Early-Onset Parkinsonism Is a Manifestation of the PPP2R5D p.E200K MutationChristine Y Kim, Thomas Wirth, Cécile Hubsch, et al.
Faraday Discussions|October 18, 2023
Flow cells and reactor design: general discussionAnas Alkayal, Mickaël Avanthay, Belen Batanero, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2024
Rare Missense Variants in KCNJ10 Are Associated with Paroxysmal Kinesigenic DyskinesiaThomas Wirth, Emmanuel Roze, Clarisse Delvallée, et al.
Brain, Behavior, and Immunity|June 18, 2019
STAT6 mediates the effect of ethanol on neuroinflammatory response in TBIFlorian Olde Heuvel, Sarah Holl, Akila Chandrasekar, et al.
Plos One|July 24, 2020
Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitisTorsten Diesinger, Vyacheslav Buko, Alfred Lautwein, et al.
The New England Journal of Medicine|December 27, 2013
Deficiency of innate and acquired immunity caused by an IKBKB mutationUlrich Pannicke, Bernd Baumann, Sebastian Fuchs, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2023
Natural History and Phenotypic Spectrum of GAA-FGF14 Sporadic Late-Onset Cerebellar Ataxia (SCA27B)Thomas Wirth, Guillemette Clément, Clarisse Delvallée, et al.
Oncology Research|May 1, 2026
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort StudyLaura Duzzi, Nora Möhn, Emily Narten, et al.
Journal of Hepatology|July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE studyDo-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.
Cancer Medicine|January 26, 2025
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG StudyJonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, et al.
Pageof 40

Showing results (351-360 of 392) with videos related to

Sort By:
Pageof 40
Annals of Neurology|August 4, 2020
Early-Onset Parkinsonism Is a Manifestation of the PPP2R5D p.E200K MutationChristine Y Kim, Thomas Wirth, Cécile Hubsch, et al.
Faraday Discussions|October 18, 2023
Flow cells and reactor design: general discussionAnas Alkayal, Mickaël Avanthay, Belen Batanero, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2024
Rare Missense Variants in KCNJ10 Are Associated with Paroxysmal Kinesigenic DyskinesiaThomas Wirth, Emmanuel Roze, Clarisse Delvallée, et al.
Brain, Behavior, and Immunity|June 18, 2019
STAT6 mediates the effect of ethanol on neuroinflammatory response in TBIFlorian Olde Heuvel, Sarah Holl, Akila Chandrasekar, et al.
Plos One|July 24, 2020
Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitisTorsten Diesinger, Vyacheslav Buko, Alfred Lautwein, et al.
The New England Journal of Medicine|December 27, 2013
Deficiency of innate and acquired immunity caused by an IKBKB mutationUlrich Pannicke, Bernd Baumann, Sebastian Fuchs, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 20, 2023
Natural History and Phenotypic Spectrum of GAA-FGF14 Sporadic Late-Onset Cerebellar Ataxia (SCA27B)Thomas Wirth, Guillemette Clément, Clarisse Delvallée, et al.
Oncology Research|May 1, 2026
Elevated C-Reactive Protein as a Potential Biomarker for Neurological Adverse Events in Immune Checkpoint Inhibitor Therapy: A Prospective Cohort StudyLaura Duzzi, Nora Möhn, Emily Narten, et al.
Journal of Hepatology|July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE studyDo-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.
Cancer Medicine|January 26, 2025
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG StudyJonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, et al.
Pageof 40